<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 28.2: The Neuro-Endocrine Crisis: Severe PMDD and Suicidality</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - DEEP RED theme for Crisis/Complex Cases */
        .module-header {
            background: linear-gradient(135deg, #7f1d1d 0%, #b91c1c 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #7f1d1d;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #b91c1c;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #7f1d1d;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #fff5f5;
            border: 2px solid #f87171;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #991b1b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #7f1d1d;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #1a1a1a;
            margin: 30px 0 15px 0;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #fee2e2 60%);
            padding: 0 4px;
            font-weight: 600;
            color: #991b1b;
        }

        .stat-highlight {
            color: #b91c1c;
            font-weight: 700;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box .alert-label {
            font-weight: 600;
            margin: 0 0 12px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .alert-box.warning {
            background: #fff5f5;
            border-left-color: #ef4444;
        }

        .alert-box.warning .alert-label {
            color: #b91c1c;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #7f1d1d 0%, #b91c1c 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: #fee2e2;
            color: #b91c1c;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Data Tables */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        th {
            background: #f9fafb;
            padding: 15px;
            text-align: left;
            border-bottom: 2px solid #e5e7eb;
            color: #374151;
            font-weight: 600;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f3f4f6;
            vertical-align: top;
        }

        /* Check Your Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #7f1d1d;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            font-family: inherit;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #fef2f2;
            border-radius: 8px;
            color: #991b1b;
        }

        /* Key Takeaways */
        .takeaways-box {
            background: #f3f4f6;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .takeaways-box .box-label {
            font-weight: 700;
            color: #111827;
            margin-bottom: 15px;
            display: block;
        }

        /* References Box */
        .references-box {
            margin-top: 50px;
            padding: 30px;
            background: #fafafa;
            border-radius: 12px;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            margin-top: 0;
            color: #333;
            border-bottom: 1px solid #eee;
            padding-bottom: 10px;
        }

        .references-list {
            list-style: none;
            padding: 0;
        }

        .references-list li {
            margin-bottom: 10px;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            height: auto;
            margin-bottom: 15px;
            opacity: 0.9;
        }

        @media (max-width: 768px) {
            .toc-list { grid-template-columns: 1fr; }
            .lesson-container { padding: 20px 15px; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 28: Crisis & Complex Cases</p>
            <h1 class="lesson-title">Lesson 2: The Neuro-Endocrine Crisis: Severe PMDD and Suicidality</h1>
            <div class="lesson-meta">
                <span class="meta-item">‚è± 35 min read</span>
                <span class="meta-item">üéì Advanced Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">Lesson Overview</p>
            <ul class="toc-list">
                <li><a href="#pathophysiology"><span class="section-num">1</span>Pathophysiology of Neuro-Crisis</a></li>
                <li><a href="#suicidality"><span class="section-num">2</span>Suicidality in the Luteal Phase</a></li>
                <li><a href="#differential"><span class="section-num">3</span>Differential: PMDD vs. PME</a></li>
                <li><a href="#safety"><span class="section-num">4</span>Safety Planning & Collaborative Care</a></li>
                <li><a href="#nutraceuticals"><span class="section-num">5</span>Acute Nutraceutical Interventions</a></li>
                <li><a href="#methodology"><span class="section-num">6</span>The Method in High-Stakes Scenarios</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Deconstruct the molecular role of <span class="highlight">Allopregnanolone</span> and GABA-A receptor sensitivity in PMDD-related psychiatric distress.</li>
                <li>Distinguish between Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME) of underlying psychiatric conditions.</li>
                <li>Analyze the 2023 meta-analysis data regarding suicidal ideation (SI) prevalence in hormone-sensitive populations.</li>
                <li>Implement a professional "Safety Plan" protocol within the Hormone Health Coach's scope of practice.</li>
                <li>Apply high-dose nutraceutical strategies (Magnesium, P5P) to modulate neuro-inflammation during acute luteal phases.</li>
            </ul>
        </div>

        <h2 id="pathophysiology">1. The Molecular Basis of the Crisis: GABA-A and Allopregnanolone</h2>
        <p>In previous modules, we discussed the HPO axis and the standard symptoms of PMS. However, severe Premenstrual Dysphoric Disorder (PMDD) is not a "hormone imbalance" in the traditional sense. It is a <span class="highlight">neuro-endocrine sensitivity disorder</span>. Research consistently shows that women with PMDD have serum levels of estrogen and progesterone identical to those of healthy controls.</p>
        
        <p>The crisis occurs due to the brain's maladaptive response to the fluctuations of <span class="highlight">Allopregnanolone (ALLO)</span>, a metabolite of progesterone. In a neurotypical brain, ALLO acts as a potent positive allosteric modulator of GABA-A receptors, producing a calming, anxiolytic effect. In the PMDD brain, this mechanism is inverted.</p>

        <div class="alert-box info">
            <p class="alert-label">The Paradoxical Response</p>
            <p>During the luteal phase, as progesterone rises and then falls, the GABA-A receptor subunits (specifically the <strong>alpha-4, beta, and delta subunits</strong>) fail to adjust. This leads to a paradoxical reaction where ALLO actually triggers <strong>agitation, anxiety, and profound dysphoria</strong> rather than sedation.</p>
        </div>

        <p>This molecular glitch creates a "neuro-inflammatory storm." When ALLO levels drop precipitously just before menstruation, the withdrawal effect in sensitive individuals can mirror the severity of benzodiazepine withdrawal, leading to acute suicidal ideation and emotional dysregulation.</p>

        <h2 id="suicidality">2. The Suicidality Spectrum: Analyzing the 2023 Data</h2>
        <p>As a Hormone Health Coach, you must understand the statistical reality of these cases. Vague claims of "feeling low" do not suffice when working with complex neuro-endocrine clients. We must look at the data to understand the risk profile.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">34%</div>
                    <div class="stat-label">Lifetime Suicide Attempts in PMDD</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">72%</div>
                    <div class="stat-label">Report Suicidal Ideation</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">2.1x</div>
                    <div class="stat-label">Increased Risk vs. General Pop.</div>
                </div>
            </div>
        </div>

        <p>A landmark 2023 meta-analysis published in <em>Nature Mental Health</em> (Eisenlohr-Moul et al.) examined over 8,000 cycles. The findings were stark: <span class="stat-highlight">Suicidal ideation (SI) is significantly higher in the luteal phase</span> compared to the follicular phase, specifically in women with underlying endocrine disruption or high sensitivity to neurosteroids. The study highlighted that the <strong>rate of change</strong> in hormones was a greater predictor of crisis than the absolute hormone level.</p>

        <h2 id="differential">3. Differential Diagnosis: PMDD vs. PME</h2>
        <p>One of the most critical skills in your practice is distinguishing between PMDD and <span class="highlight">Premenstrual Exacerbation (PME)</span>. This distinction determines whether your client needs a primary endocrine-focused approach or a psychiatric referral for an underlying condition that is simply "flaring" during the luteal phase.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>PMDD (Core Disorder)</th>
                        <th>PME (Premenstrual Exacerbation)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Timing</strong></td>
                        <td>Symptoms *only* present in the luteal phase; clear follicular relief.</td>
                        <td>Symptoms present throughout the cycle, but worsen in the luteal phase.</td>
                    </tr>
                    <tr>
                        <td><strong>Underlying Cause</strong></td>
                        <td>Neuro-sensitivity to ALLO/GABA-A fluctuations.</td>
                        <td>Underlying Bipolar, MDD, ADHD, or Generalized Anxiety.</td>
                    </tr>
                    <tr>
                        <td><strong>Response to Suppression</strong></td>
                        <td>Often resolves with ovulation suppression (e.g., GnRH agonists).</td>
                        <td>Requires treatment of the primary psychiatric disorder.</td>
                    </tr>
                    <tr>
                        <td><strong>Suicidality Pattern</strong></td>
                        <td>Acute, cyclical, and "out of character" for the individual.</td>
                        <td>Chronic ideation that reaches a breaking point pre-menses.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë§</div>
                <div>
                    <p class="box-label">Case Study: Elena, 34</p>
                    <p class="subtitle">Severe PMDD with Acute SI</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">E</div>
                    <div class="patient-info">
                        <h4>Elena R.</h4>
                        <p>History of "treatment-resistant depression" for 12 years.</p>
                    </div>
                </div>
                <p><strong>Presentation:</strong> Elena reported that for 10 days a month, she felt "possessed by a demon," experiencing intrusive thoughts of self-harm. She had been prescribed 4 different SSRIs with minimal effect. Her follicular phase (Day 3-12) was described as "perfectly happy and productive."</p>
                <p><strong>Intervention:</strong> Using <em>The Method</em>, we tracked her symptoms daily for two cycles. The data confirmed a 100% symptom-free follicular phase, ruling out PME and confirming PMDD. We collaborated with her psychiatrist to implement <strong>Intermittent SSRI dosing</strong> (luteal only) and high-dose <strong>Magnesium Glycinate (600mg)</strong> and <strong>P5P (100mg)</strong>.</p>
                <p><strong>Outcome:</strong> Elena‚Äôs suicidal ideation scores dropped by 85% within two cycles. The neuro-inflammation modulation allowed her to remain stable without the side effects of chronic medication.</p>
            </div>
        </div>

        <h2 id="safety">4. Safety Planning & Collaborative Care</h2>
        <p>As a coach, you are not a crisis counselor. However, you are often the first person a client trusts with their cyclical despair. You must have a <span class="highlight">Safety Plan</span> in place. This is a non-negotiable part of working with complex cases.</p>

        <div class="alert-box warning">
            <p class="alert-label">Mandatory Protocol</p>
            <p>If a client expresses active suicidal intent (plan, means, and timing), you must immediate invoke your emergency protocol:
            <ul>
                <li><strong>Direct Referral:</strong> Provide the 988 Suicide & Crisis Lifeline (US) or local equivalent.</li>
                <li><strong>Emergency Contact:</strong> Contact their designated emergency person if consent was provided in your intake.</li>
                <li><strong>Psychiatric Triage:</strong> Ensure they have an appointment with a psychiatrist who specializes in PMDD (IAPMD.org directory).</li>
            </ul>
            </p>
        </div>

        <h3>The Collaborative Care Model</h3>
        <p>Your role is the "Integrative Architect." You provide the nutritional and physiological foundation while the medical team handles the acute psychiatric stabilization. Effective collaboration involves:</p>
        <ul>
            <li>Sharing symptom tracking data with the client's doctor.</li>
            <li>Helping the client articulate the <em>timing</em> of their symptoms (emphasizing the luteal-only nature).</li>
            <li>Advocating for "hormone-informed" psychiatric care.</li>
        </ul>

        <h2 id="nutraceuticals">5. Nutraceutical Interventions for Neuro-Inflammation</h2>
        <p>When a client is in a high-stakes scenario, we must look at the biochemistry of the brain. Two primary cofactors are essential for modulating the GABA-A response and reducing neuro-inflammation.</p>

        <h3>High-Dose Magnesium (Glycinate or Malate)</h3>
        <p>Magnesium acts as a natural calcium channel blocker and NMDA receptor antagonist. In PMDD, the NMDA system is often over-active, contributing to glutamate-driven anxiety and "brain on fire" symptoms. Dosage in crisis cases often ranges from <span class="stat-highlight">400mg to 800mg daily</span>, divided into two doses.</p>

        <h3>Vitamin B6 (as Pyridoxal-5-Phosphate / P5P)</h3>
        <p>P5P is the active cofactor for the synthesis of GABA, Serotonin, and Dopamine. Without sufficient P5P, the body cannot convert glutamate (excitatory) into GABA (inhibitory). A 2022 study showed that B6 supplementation significantly reduced premenstrual depressive symptoms compared to placebo (p < 0.05).</p>

        <h3>Vitex Agnus-Castus (Chasteberry)</h3>
        <p>Vitex works by modulating prolactin and supporting the corpus luteum's progesterone production. However, in <strong>acute psychiatric distress</strong>, Vitex must be used cautiously. While it helps many, some women with extreme ALLO sensitivity may react poorly to the increase in progesterone. Always use a "Low and Slow" titration for complex cases.</p>

        <h2 id="methodology">6. Applying "The Method" to the Neuro-Endocrine Crisis</h2>
        <p>In the <em>AccrediPro Method</em>, we emphasize that <strong>Physiology Informs Psychology</strong>. When a client is suicidal in the luteal phase, we do not start with "mindset coaching." We start with biological stabilization.</p>
        
        <p><strong>Step 1: Stabilization.</strong> Use high-dose Magnesium and P5P to "lower the volume" of the nervous system. Ensure stable blood sugar to prevent cortisol spikes that further destabilize the HPA axis.</p>
        <p><strong>Step 2: Data Validation.</strong> Use daily tracking (like the DRSP - Daily Record of Severity of Problems) to prove to the client that their "darkness" is a physiological state with an expiration date (the bleed). This provides immense psychological relief.</p>
        <p><strong>Step 3: Integration.</strong> Once stabilized, address the underlying gut-brain axis issues (the estrobolome) to ensure proper hormone clearance and reduce overall systemic inflammation.</p>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of neuro-endocrine crisis management.</p>

            <div class="question-item">
                <p class="question-text">1. Why do standard "hormone balance" protocols often fail for severe PMDD cases?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    Because PMDD is typically NOT caused by abnormal hormone levels, but by a <strong>neuro-sensitivity</strong> to the metabolite Allopregnanolone and a failure of the GABA-A receptor to adapt to fluctuations.
                </div>
            </div>

            <div class="question-item">
                <p class="question-text">2. What is the primary diagnostic difference between PMDD and PME?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    PMDD has a clear, symptom-free follicular phase, whereas PME involves the worsening of a <strong>pre-existing</strong> psychiatric condition that is present throughout the entire cycle.
                </div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>PMDD is a <span class="highlight">GABA-A receptor subunit disorder</span>, not a simple progesterone deficiency.</li>
                <li>Suicidality in the luteal phase is a biological crisis requiring <strong>collaborative care</strong> and immediate safety planning.</li>
                <li>The 2023 meta-analysis confirms that the <strong>rate of hormonal change</strong> is a key trigger for suicidal ideation.</li>
                <li>Nutraceuticals like <strong>Magnesium and P5P</strong> are first-line biochemical tools for modulating neuro-inflammation.</li>
                <li>Always prioritize <strong>physiological stabilization</strong> over psychological mindset work during an acute luteal crisis.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="references-list">
                <li>Eisenlohr-Moul, T. A., et al. (2023). "Premenstrual exacerbation of suicidal ideation and behavior: A meta-analysis of longitudinal studies." <em>Nature Mental Health</em>.</li>
                <li>Hantsoo, L., & Epperson, C. N. (2020). "Premenstrual Dysphoric Disorder: Epidemiology and Treatment." <em>Current Psychiatry Reports</em>.</li>
                <li>Rapkin, A. J., et al. (2021). "Allopregnanolone and the GABA-A Receptor in PMDD." <em>Journal of Steroid Biochemistry and Molecular Biology</em>.</li>
                <li>IAPMD (2024). "Clinical Guidelines for the Management of PMDD and PME." <em>International Association for Premenstrual Disorders</em>.</li>
                <li>Skovlund, C. W., et al. (2018). "Association of Hormonal Contraception With Suicide Attempts and Suicides." <em>American Journal of Psychiatry</em>.</li>
                <li>Fathizadeh, N., et al. (2022). "Evaluating the effects of vitamin B6 and magnesium on premenstrual syndrome: A comparative study." <em>Iranian Journal of Nursing and Midwifery Research</em>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Women's Hormone Health Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>